For many people with IgA nephropathy (IgAN), a condition in which immunoglobulin A (IgA) antibodies accumulate in the kidneys and trigger inflammation, kidney function stays stable for many years. For ...

First-in-human study of EPI-326 will evaluate the company's lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to expand to CRC AACR 2026 presentations, including New ...

Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...

In this episode of The OncoloGIST, Dr Christine Bestvina of UChicago Medicine provides a comprehensive look at the rapidly ...

The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

EGFR-positive lung cancer is more common in non-smokers (particularly those with adenocarcinoma) and younger adults, as it often develops from a single genetic mutation rather than widespread DNA ...

CNS metastases in EGFR-mutant NSCLC are prevalent and worsen prognosis, especially with acquired progression during treatment. Amivantamab plus lazertinib shows promising CNS activity, but current ...